News & Events zu Cryoport Inc (CYRX)CYRXCryoport Inc

Cryoport Reports Q2 Revenue of $49M

Reports Q2 revenue $49M, consensus $48.21M. Jerrell Shelton, CEO of Cryoport, commented, "Our revenue momentum over the past several periods continued into the second quarter, with total revenue reaching $49.0 million. Life Sciences Services revenue grew 15% year-over-year, led by 25% growth in BioStorage/BioServices revenue. Our Life Sciences Products business also generated solid results during the quarter, driven by continued demand for MVE Biological Solutions' industry-leading cryogenic systems and the successful introduction of new and innovative products."

Cryoport Reports Q1 Revenue of $47.8M

Reports Q1 revenue $47.8M, consensus $44.86M. Jerrell Shelton, CEO of Cryoport, commented, "Cryoport delivered a strong start to 2026 with first-quarter revenue of $47.8 million, up 16% year-over-year, reflecting a continuation of our momentum over the past several quarters across our integrated services and products platform. Revenue in support of commercial Cell and Gene Therapies grew 26% to $9.1 million, while clinical trial support revenue grew 18% to $12.9 million. We continue to support one of the industry's broadest CGT pipelines, and our leadership across both clinical and commercial programs positions us well for sustainable growth."

Cryoport Q4 Revenue $45.45M Exceeds Expectations

Reports Q4 revenue $45.45M, consensus $42.92M. Jerrell Shelton, CEO of Cryoport, commented, "2025 was a year of strong progress for Cryoport. We delivered full-year revenue of $176.2M, exceeding the high end of our previous guidance and reflecting continued momentum across our core markets. We achieved double-digit revenue growth driven by expanding cell and gene therapy activity, with revenue from the support of commercial CGTs increasing 29% year-over-year to a record $33.4M for FY25. Revenue from the support of clinical trials also remained solid, growing 14% to $47.1M for FY 2025. At year-end, we supported a record 760 global clinical trials, representing approximately 70% of CGT trials. We believe our leadership position across both clinical and commercial programs, and the breadth of the development pipeline we support, provide a substantial foundation for sustained long-term growth."